Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 10 , ISSUE 3 ( July-September, 2018 ) > List of Articles

ORIGINAL ARTICLE

Does Cabergoline Help in Decreasing Chronic Pelvic Pain Due to Endometriosis Compared to Medroxyprogesterone Acetate? A Prospective Randomized Study

Partha Mukhopadhyay, Amit Kyal, Aprateem Mukhopadhyay

Keywords : Cabergoline, Chronic pelvic pain, Endometriosis, Medroxyprogesterone acetate.

Citation Information : Mukhopadhyay P, Kyal A, Mukhopadhyay A. Does Cabergoline Help in Decreasing Chronic Pelvic Pain Due to Endometriosis Compared to Medroxyprogesterone Acetate? A Prospective Randomized Study. J South Asian Feder Obs Gynae 2018; 10 (3):167-169.

DOI: 10.5005/jp-journals-10006-1582

Published Online: 01-07-2015

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Introduction: Endometriosis is a chronic debilitating disease which adversely affects the equality of life of the woman. The exact pathophysiology of the disease and cause of pain is not clearly understood and so confounds an attempt to select the most favourable clinical management. The study aims to assess the safety and efficacy of cabergoline with respect to medroxyprogesterone acetate in treatment of chronic pelvic pain (CPP) due to endometriosis. Materials and methods: This study was conducted in Medical College, Kolkata from June 2015 to June 2016. Eighty patients of chronic pelvic pain due to endometriosis (diagnosed by USG and laparoscopy) were randomly assigned into two groups of 40 each receiving either medroxyprogesterone acetate (10 mg TDS) or cabergoline (0.5 mg twice weekly) for 12 weeks. Response for pain was measured on a visual analog scale (VAS) of 0–10 scale at the beginning of treatment and at intervals of 1, 3, 4 and 6 months. Results: The study shows that the decrease in pain scores at various time points was statistically significant in both the groups. However, when the two groups were compared among themselves the reduction in VAS score at various time points were not statistically significant. Patients receiving medroxyprogesterone acetate had more side effects (67.5%) compared to cabergoline (47.5%). The most common side effect in medroxyprogesterone acetate group was amenorrhea (25%) whereas, in the cabergoline group, it was nausea and vomiting (45%). Conclusion: Cabergoline and medroxyprogesterone acetate are equally effective in decreasing chronic pelvic pain due to endometriosis. However, due to lesser side effects and less frequent dosing, cabergoline has a better acceptance and compliance than medroxyprogesterone acetate. Thus cabergoline can be a better alternative to medroxyprogesterone acetate.


PDF Share
  1. Berek and Novak's Gyecology:15th edition 2012;506-7
  2. Berek and Novak's Gyecology:15th edition 2012 :487-88
  3. May K, Becker CM. Endometriosis and angiogenesis. Minerva ginecologica. 2008 Jun;60(3):245-254.
  4. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996 Jan;11:220-223.
  5. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998 Jun;13(6):1686-1690.
  6. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001 May;7(5):569-574.
  7. Novella-Maestre E, Carda C, Ruiz-Sauri A, Garcia-Velasco JA, Simon C et al. Identification and quantification of dopamine receptor 2 in human entropic and ectopic endometrium; a novel molecular target for endometriosis therapy. Biol Reprod 2010 Nov;83(5):866-873.
  8. Novella-Maestre E, Carda C, Noguera I, Ruiz-Sauri A, Garcia- Velasco JA, Simon C. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009 May;24(5):1025-1035.
  9. Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Marshall LM, Hunter DJ. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric and lifestyle factors. Am J Epidemiology.2004 Oct;160(8):784-796
  10. Abbas S, Ihle P, Koster I, Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms:findings from a statutory health insurance based cohort in Germany. Eur J Obstet Gynecol Reprod Biol. 2012 Jan;160(1):79-83
  11. Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynaecol. 1988 Sep;72:323-327
  12. Gunning JE, Moyer D. The effect of medroxyprogesterone acetate on endometriosis in the human female. Fertil Steril 1967 Nov-Dec;18:759-774
  13. Hamid AM, Madkour WA, Moawad A, Elzaher MA, Roberts MP. Does Cabergoline help in decreasing endometrioma size compared to LHRH agonist?A prospective randomized study. ArchGynaecol Obstet. 2014 March;290(4):677-682.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.